August 12, 2019  HOOFDDORP, The Netherlands–(BUSINESS WIRE)–Bioventus, a global leader in orthobiologic solutions, is launching DUROLANE SJ (1mL), and has received expanded indications for DUROLANE (3mL), its single-injection joint-fluid osteoarthritis (OA) treatment, in Australia and New Zealand. Both are hyaluronic acid (HA)-based products and available from LMT Surgical. DUROLANE SJ (1mL) has been approved by Australia’s Therapeutic Goods Association (TGA) …